Market Newsdesk

CALGARY, Alberta, Dec. 10, 2020 (GLOBE NEWSWIRE) — CEMATRIX Corporation (TSXV: CVX) (the “Corporation” or “CEMATRIX”) is pleased to announce the appointment of Randy Boomhour as Chief Financial Officer of the Company, effective December 10, 2020, replacing James Chong who will be leaving the Company effective December 9, 2020.

Mr. Boomhour has over 20 years experience in senior financial leadership positions serving both private and publicly listed companies. Mr. Boomhour is a Chartered Professional Accountant and currently serves as VP Finance in the Industrial Group of Stuart Olson Inc.(TSX: SOX, SOX.DB.A).

Jeff Kendrick, President and Chief Executive Officer, stated: “The Board and I feel very fortunate to have Randy’s wide-ranging financial management expertise to call on as we continue to execute our strategic plans for 2021 and beyond. Randy will play a key role as CEMATRIX continues on its growth trajectory. We also want to thank James for his invaluable service during his time with the Company. We wish him the very best in his future endeavours.”

ABOUT CEMATRIX

CEMATRIX is a rapidly growing, cash flow positive company that manufactures and supplies technologically advanced cellular concrete products developed from proprietary formulations across North America. This unique cement-based material with superior thermal protection delivers cost-effective, innovative solutions to a broad range of problems facing the infrastructure, industrial (including oil and gas) and commercial markets. Through recent acquisitions of Chicago based MixOnSite and Bellingham based Pacific International Grout, CEMATRIX is now North America’s largest Cellular Concrete company.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Jeff Kendrick – President and Chief Executive Officer
Phone: (403) 219-0484

Glen Akselrod – President, Bristol Capital
Phone: (905) 326 1888 ext 1
[email protected]

Jeff Walker – Vice President, The Howard Group
Phone: (888) 221-0915 or (403) 221-0915
[email protected]

WILMETTE, Ill. and BELOIT, Wis., Dec. 10, 2020 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing a urokinase plasminogen activator receptor targeted radio-immuno-therapeutic (uPRIT) for the potential treatment of severe COVID-19, today announced the selection of a uPRIT clinical candidate. Monopar and NorthStar partnered with IsoTherapeutics Group LLC to generate a panel of uPRIT leads, which were then screened by Aragen Bioscience Inc., resulting in the identification of a uPRIT clinical candidate plus several backup candidates.

uPRITs are analogs of MNPR-101, Monopar’s proprietary humanized urokinase plasminogen activator receptor (uPAR) targeted antibody, that have been modified to enable attachment of a therapeutic radioisotope. uPRITs bind to uPAR with high affinity and are thought to selectively recognize the aberrantly activated, pro-inflammatory immune cells that express this target and also seem to be mediating the cytokine storm leading to respiratory failure and poor outcomes in severe COVID-19 patients.

The cleaved, blood-circulating soluble form of uPAR, suPAR, has been gaining attention as a potentially important prognostic biomarker for severe COVID-19 in several recently published studies. Rovina et al. 2020 showed that patients with elevated levels of suPAR at the time of hospital admission are 17 times more likely to develop severe respiratory failure (p=0.0000000012); Arnold et al. 2020 showed suPAR to have the best performance in predicting outcome (such as intensive care unit admission and death) of all the biomarkers examined; and Eugen-Olsen et al. 2020 showed that low levels of suPAR are predictive of mild outcome in COVID-19 patients.

The aim with uPRITs is to bind to and rapidly eliminate the aberrantly activated immune cells, quickly shutting down the cytokine storm. If uPRITs are effective in this setting, they may also be effective in treating other diseases characterized by rapid and severe systemic inflammatory responses, including certain pneumonias and sepsis.

The uPRIT with the most attractive uPAR binding profile was selected to advance into IND-enabling studies. “Selection of a uPRIT candidate allows us to begin preclinical studies, and brings us one step closer to reaching human clinical trials,” said Andrew Mazar, Ph.D., Chief Scientific Officer of Monopar. “Even when SARS-CoV2 vaccines are available, treatments will be needed for those who are not vaccinated, or for patients for whom the vaccine is not effective, and who thereby contract severe COVID-19. Successfully combatting COVID-19 over the long term will require a combination of preventive and treatment approaches.”

“This rapid advancement of our uPRIT program highlights the innovation and collaborative efforts of Monopar, NorthStar and our partners,” stated James Harvey, Ph.D., Senior Vice President and Chief Scientific Officer of NorthStar. “Selecting a highly specific therapeutic candidate for the potential treatment of severe COVID-19 in short order is a significant achievement.”

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar’s pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; and a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19. For more information, visit: www.monopartx.com. Follow Monopar on LinkedIn and Twitter.

About NorthStar Medical Radioisotopes, LLC

NorthStar Medical Radioisotopes is a global innovator in the production and distribution of radioisotopes used for medical imaging and therapeutic purposes. NorthStar is a company committed to providing the United States with reliable and environmentally friendly radioisotope supply solutions to meet the needs of patients and to advance clinical research. The Company’s first product is the RadioGenix® System (technetium Tc 99m generator), an innovative and flexible platform technology initially approved by the U.S. Food and Drug Administration in February 2018. For more information, visit: www.northstarnm.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include statements concerning: the selected MNPR-101 derived uPRIT’s ability to mediate the cytokine storm which leads to respiratory failure and poor outcomes in severe COVID-19 patients; whether biomarkers in published studies can be repeated in uPRIT preclinical and clinical studies; uPRIT’s ability to be effective in treating other diseases characterized by rapid and severe systemic inflammatory responses, including certain pneumonias and sepsis; and whether uPRITs will be successful in preclinical studies or move forward into clinical trials in patients with severe COVID-19. The forward-looking statements involve risks and uncertainties including, but not limited to, the lack of any clinical activities to date with respect to MNPR-101, the requirement for additional capital to complete preclinical and clinical development and for potential commercialization, the uPRIT not being able to kill aberrantly activated cytokine producing immune cells, the uPRIT not being able to use uPAR to gain entry into these cells and release this cytotoxic payload to kill these cells while sparing normal tissue, not being able to ensure volumes of this radioisotope can be manufactured and scaled up to meet potential demand, uncertainties about levels of demand when vaccines are widely utilized or treatments are approved for marketing and available for commercialization and the significant general risks and uncertainties surrounding the research, development, regulatory approval and commercialization of therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar and NorthStar undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s and NorthStar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

CONTACTS:

For Monopar Therapeutics Inc.

Investor Relations:
Kim R. Tsuchimoto
Chief Financial Officer
[email protected]

For NorthStar Medical Radioisotopes, LLC
.

Investor Relations:
Paul Estrem
Senior Vice President and Chief Financial Officer
[email protected]

BOSTON and NASHVILLE, Tenn., Dec. 10, 2020 (GLOBE NEWSWIRE) — The Nashville Predators and DraftKings Inc. (Nasdaq: DKNG) announced today a new multi-year deal, which will make DraftKings the Official Daily Fantasy Sports Provider and an Official Sports Betting Operator of the team. The agreement comes on the heels of DraftKings launching its top-rated mobile sportsbook app in Tennessee.

“As soon as the Tennessee Sports Gaming Act was passed in April, we immediately began our search for an experienced sports betting partner,” said Chris Junghans, EVP & Chief Revenue Officer, Nashville Predators. “With legal sports betting now live in Tennessee, we are thrilled to announce our formal relationship with industry-leading DraftKings. Through this multi-year agreement, Predators fans across the state will have access to the GOLD STANDARD of sports betting information technology, which provides a competitive, reliable and responsible platform. We look forward to entering this new era of Tennessee sports fandom together and also to seeing everything that this partnership will bring to our state and to our fans.”

In an ongoing effort to create the best possible viewing experience for fans while offering new and exciting ways to engage with the team, this partnership with DraftKings will allow the Nashville Predators to safely bring fans closer to the game of hockey. As a benefit to Preds fans across the state of Tennessee, the Predators and DraftKings are offering a deposit bonus of up to $1,000 when signing up with DraftKings Sportsbook by downloading the DraftKings mobile app*.

“After recently launching the top-rated DraftKings Sportsbook app in Tennessee, we are thrilled to continue our momentum in the state by announcing our latest team deal with the Nashville Predators,” said Ezra Kucharz, Chief Business Officer, DraftKings. “As a result of this collaboration, Predators fans will get the full DraftKings experience both on and off the ice as we look forward to the return of hockey season.”

Per the agreement, DraftKings’ branding and content will be integrated throughout Bridgestone Arena including static dasher boards and virtual signage visible on TV for all regionally broadcast Predators games. Signage for DraftKings will also be incorporated on the Lexus Lounge LED screen for all regular and postseason Predators home games. Additionally, DraftKings sports betting lines will be prominently showcased during both pre-game and in-game radio spots.

In addition to in-arena branding, DraftKings and the Nashville Predators will partner on digital and social media content, with DraftKings takeovers of the Predators homepage, app integration and social media giveaways. DraftKings will also have a regular presence in “This Week in Smashville,” the Predators’ newsletter.

Fans can access DraftKings Sportsbook and Daily Fantasy Sports apps anywhere by visiting DraftKings.com or by downloading the DraftKings app via iOS and Android.

* Gambling problem? Call or text the Tennessee Redline at 800-889-9789. 21+ Tenn. only. Deposit bonus requires 25x play through. Eligibility restrictions apply. See

DraftKings.com/sportsbook

for full terms and conditions.

ABOUT THE NASHVILLE PREDATORS

The Nashville Predators became the National Hockey League’s 27th team on May 4, 1998 and in 22 seasons have developed into one of the League’s premier franchises and a model of consistency throughout the hockey world. Each season, the organization works tirelessly to reach its ONE GOAL of becoming a Stanley Cup Champion hockey team while making Bridgestone Arena the No. 1 sports and entertainment venue in the United States. Located in the heart of Music City – a world-renowned destination for music and entertainment – the Predators have established themselves as of the NHL’s top teams on and off the ice. Playing in front of sold-out crowds at Bridgestone Arena, the Predators have qualified for the postseason in six straight campaigns, tied for the second-longest active streak in the NHL. In addition to advancing to the Stanley Cup Final in 2017, the Predators won the Presidents’ Trophy in 2017-18 and their second consecutive Central Division title in 2018-19.

ABOUT DRAFTKINGS

DraftKings Inc. (Nasdaq: DKNG) is a digital sports entertainment and gaming company created to fuel the competitive spirit of sports fans with products that range across daily fantasy, regulated gaming and digital media. Headquartered in Boston, and launched in 2012 by Jason Robins, Matt Kalish and Paul Liberman, DraftKings is the only U.S.-based vertically integrated sports betting operator. DraftKings is a multi-channel provider of sports betting and gaming technologies, powering sports and gaming entertainment for 50+ operators in 17 countries. DraftKings’ Sportsbook is live with mobile and/or retail betting operations in the United States pursuant to regulations in Colorado, Illinois, Indiana, Iowa, Mississippi, New Hampshire, New Jersey, New York, Oregon, Pennsylvania, Tennessee and West Virginia. DraftKings’ daily fantasy sports product is available in 8 countries internationally with 15 distinct sports categories. DraftKings is the official daily fantasy partner of the NFL, MLB and the PGA TOUR as well as an authorized gaming operator of the NBA and MLB and an official betting operator of the PGA TOUR.

FORWARD-LOOKING STATEMENTS

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside DraftKings’ control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see DraftKings’ Securities and Exchange Commission filings. DraftKings does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Media Contact

[email protected]




@DraftKingsNews

Investor Contact

[email protected]

TEMPE, Ariz., Dec. 10, 2020 (GLOBE NEWSWIRE) — WRAP Technologies, Inc. (the “Company” or “WRAP”) (Nasdaq: WRAP), an innovator of modern policing solutions, announced today that it bid and was selected by the United Kingdom Ministry of Defence into their Defence and Security Accelerator (DASA) for ‘Advancing Less Lethal Weapons.’

The Defence and Security Accelerator (DASA) finds and funds exploitable innovation to support UK defence and security. DASA sought proposals for innovative technologies that allow law enforcement officers to safely prevent the escalation of conflict from long ranges during serious or violent circumstances. In the first phase of the program, WRAP’s engineering team will focus on developing proof of concept prototypes of longer-range remote restraint solutions.

“We are honored to be selected by DASA to explore and pursue further remote restraint solutions,” said Tom Smith, President and Interim CEO at WRAP. “We believe this selection reflects the value of our technology as well as the confidence in WRAP as a leader in the law enforcement technology space. It further validates the investment we have made in our skilled engineering team.

“This opportunity also gives WRAP and our UK distributor continued exposure to high ranking officials in the United Kingdom Ministry of Defence to help further our efforts towards BolaWrap adoption throughout the United Kingdom.”

In a report on the Efficacy and Safety of BolaWrap published earlier this year, use of force experts in the United Kingdom recommended all frontline officers carry the BolaWrap and that BolaWrap be placed below handcuffs on the use of force continuum.

“This is an important and very exciting step in recognizing the BolaWrap remote restraint technology as a viable solution for police officers in the UK,” said Jags Gill, Director of International Sales at WRAP. “We believe BolaWrap could provide UK police forces and personnel with a tactical advantage when dealing with noncompliant suspects.”

The DASA funding award is pending the completion of relevant governance requirements expected this month.

About WRAP
WRAP Technologies, Inc. is an innovator of modern policing solutions. The Company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar® tether to restrain an individual at a distance from 10 to 25 feet. Developed by award winning inventor Elwood Norris, the Company’s Chief Technology Officer, the small but powerful BolaWrap 100 assists law enforcement in safely and effectively deescalating encounters, especially those involving an individual in crisis. BolaWrap 100 has already been used to safely apprehend suspects without injury in a number of cities including Los Angeles, Sacramento, Fresno, Bell, Albuquerque, Minneapolis, West Palm Beach, Fort Worth, and Oak Ridge. For information on the Company, please visit www.wrap.com.

Follow WRAP here:

WRAP on Facebook: https://www.facebook.com/wraptechnologies/
WRAP on Twitter: https://twitter.com/wraptechinc
WRAP on LinkedIn: https://www.linkedin.com/company/wraptechnologiesinc/

Trademark Information
BolaWrap and Wrap are trademarks of WRAP Technologies, Inc. All other trade names used herein are either trademarks or registered trademarks of the respective holders.

Cautionary Note on Forward-Looking Statements – Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to: statements regarding the Company’s overall business; total addressable market; and, expectations regarding future sales and expenses. Words such as “expect”, “anticipate”, “should”, “believe”, “target”, “project”, “goals”, “estimate”, “potential”, “predict”, “may”, “will”, “could”, “intend”, and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Moreover, forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the Company’s ability to successful implement training programs for the use of its products; the Company’s ability to manufacture and produce product for its customers; the Company’s ability to develop sales for its new product solution; the acceptance of existing and future products; the availability of funding to continue to finance operations; the complexity, expense and time associated with sales to law enforcement and government entities; the lengthy evaluation and sales cycle for the Company’s product solution; product defects; litigation risks from alleged product-related injuries; risks of government regulations; the business impact of health crises or outbreaks of disease, such as epidemics or pandemics; the ability to obtain export licenses for counties outside of the US; the ability to obtain patents and defend IP against competitors; the impact of competitive products and solutions; and the Company’s ability to maintain and enhance its brand, as well as other risk factors mentioned in the Company’s most recent annual report on Form 10-K, quarterly report on Form 10-Q, and other SEC filings. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

WRAP
Contact:

Paul M. Manley
VP – Investor Relations
(612) 834-1804
[email protected]

Denver, Dec. 10, 2020 (GLOBE NEWSWIRE) — AMP Robotics Corp. (“AMP”), a pioneer in artificial intelligence (AI) and robotics used to recover commodities reclaimed as raw materials for the global supply chain, is extending its ability to identify and pick recyclables at the brand level by working with consumer packaged goods (CPG) companies to recover higher rates of these materials. 

As the company expands its reach into other nodes of the circular economy, one of AMP’s first corporate partners is consumer beverage giant Keurig Dr Pepper (KDP) in support of its introduction of recyclable K-Cup® pods. Following KDP’s conversion of its coffee pods to polypropylene, a sought-after plastic for recycled materials, the companies worked together to equip AMP’s robotics systems to properly identify and sort K-Cup pods in recycling facilities. All of the K-Cup pods KDP produces are now recyclable. 

Monique Oxender, chief sustainability officer, Keurig Dr Pepper, explained, “Our move to recyclable plastic is a critical first step, but to make greater strides toward circularity, we need to improve acceptance and sortation so we can more readily incorporate recycled plastic back into our products and packaging. Recycling systems in the U.S. are diverse, and we need technology and infrastructure upgrades to improve the quality and quantity of recycled plastic available.”

AMP provides technology to help with this multifaceted challenge. The AI platform that guides AMP’s robotics systems can differentiate objects found in the waste stream by color, size, shape, opacity, brand, and more, contextualizing and storing information about each item it perceives. AI and machine learning enable the robotic sorting of material as granular as a type of plastic at a pick rate of upwards of 80 items per minute—more than two times as fast as human sorters, and with greater accuracy and consistency. This process produces a higher quantity and quality of plastic that suppliers of polypropylene resin can sell back to CPGs to create new packaging. AMP’s AI platform becomes smarter and more effective over time as the company deploys more robots; AMP can add limitless subcategories of brand-level material to meet market demand and distribute the functionality to identify and sort it across its fleet. 

“Intelligent plastics sortation, powered by AI, robotics, and advanced data analytics, can have cross-value chain impact and direct benefits to plastic waste generators, sorting facilities, recyclers, and consumer packaged goods companies,” said Rob Writz, director of business development for AMP Robotics. “AI-guided sortation ensures a higher-quality end product that isn’t contaminated by other materials, and a larger volume of recycled material. Collaboration across the recycling value chain will turn product and packaging waste back into the inputs for future manufacturing while growing and strengthening our recycling system.” 

In a move that demonstrates the continuous innovation of its AI capabilities, AMP has opened a new 40,000-square-foot test facility in Colorado to explore expanded applications of its technology with the goal of increasing the feedstock of recycled content for CPGs and container producers. This facility will help prototype new, economical ways to ensure recyclables are indeed recycled, even for low volumes that historically have not been economical for recovery. By lowering the cost of recycling marginal volumes, AMP aims to maximize resource recovery and quality for the manufacturing supply chain.

In July, The Recycling Partnership launched the Polypropylene Recycling Coalition to improve its recovery and recycling in the United States and further develop the end market for high-quality recycled polypropylene. The Coalition announced the first four materials recovery facilities to receive grants to fund improved sortation of polypropylene through technology like AMP’s robotics systems and support targeted consumer education efforts. KDP is a founding member of the Coalition and its largest funder; the company has committed to ongoing collaboration with industry peers and other players in the recycling ecosystem to drive meaningful change along with its financial sponsorship. The Coalition’s investments will widen total nationwide acceptance of polypropylene in curbside recycling programs by approximately 1.7% to an additional four million people, resulting in the recovery of a larger supply of polypropylene that could be made into new products. 

Oxender concluded, “Investing in ways that amplify our individual actions will enable us to truly drive progress in eliminating packaging waste by improving recycling infrastructure and enhancing consumer education efforts, both of which will increase the recovery of valuable plastics.” 

For more about the efforts of AMP and KDP to bring AI to the sorting process at recycling facilities to generate a higher-quality end product for reuse, see this Vox explainer. Further, at 1 p.m. ET today, GreenBiz is hosting a complimentary webcast about how innovation and collaboration is strengthening recycling with AMP Founder and CEO Matanya Horowitz, KDP’s Oxender, GFL Environmental’s Brent Hildebrand, and Sidewalk Infrastructure Partners’ Michael DeLucia. 

About AMP Robotics™ Corp.

AMP Robotics is modernizing the world’s recycling infrastructure by applying AI and robotics to increase recycling rates and economically recover recyclables reclaimed as raw materials for the global supply chain. The AMP Cortex™ high-speed robotics system automates the identification and sorting of recyclables from mixed material streams. The AMP Neuron™ AI platform continuously trains itself by recognizing different colors, textures, shapes, sizes, patterns, and even brand labels to identify materials and their recyclability. Neuron then guides robots to pick and place the material to be recycled. Designed to run 24/7, all of this happens at superhuman speed with extremely high accuracy. With deployments across North America, Asia, and Europe, AMP’s technology recovers recyclables from municipal waste, precious commodities from electronic waste, and high-value materials from construction and demolition debris. AMP is made in America with headquarters and manufacturing operations in Colorado.

Attachments

• AI vision with PP
• PP_Robot_Picks_AMP_2020 (1)

New Name Reflects Company’s Evolution to Advancing First-in-Class Oncology Therapies

TEL AVIV, Israel, Dec. 10, 2020 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (the “Company”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that it has changed its corporate name from Kitov Pharma Ltd. to Purple Biotech Ltd. The name change will be effective for trading purposes on the Tel Aviv Stock Exchange (TASE) and the NASDAQ Capital Market (NASDAQ) as of market open on December 22, 2020. At that time, the Company’s ordinary shares and American Depositary Shares (ADSs) will begin to trade under the new ticker symbol, “PPBT,” on the TASE and NASDAQ, respectively. The Company’s ordinary shares will continue to trade on the TASE and its ADSs will continue to trade on NASDAQ under the ticker symbol “KTOV” through market close on December 21, 2020. The Company’s ADSs were assigned a new CUSIP number (74638P109), effective on December 22, 2020, as described above.

“Over the past few years, our business has evolved significantly towards an exciting new vision and our new name, Purple Biotech, completes the transformation to our focus on advancing first-in-class oncology therapies,” said Isaac Israel, the Company’s Chief Executive Officer.

“2020 has been a year of substantial achievements for our company. We recently initiated Phase 1/2 clinical studies for NT219 and expect to begin our Phase 1/2 studies for CM24 shortly. We also successfully completed over $60 million in financings this year to support our clinical development and strategic plans. As we head into 2021, we look forward to leveraging the compelling opportunities that lie ahead of us and to advancing our objectives to increase the longevity and the quality of life of cancer patients”, added Isaac Israel.

The Company will also be relocating its corporate headquarters shortly to the Science Park near the Weizmann Institute in Rehovot, Israel, a key regional biotech hub.

No action is required by shareholders and holders of ADSs in connection with the corporate name change. The number of outstanding ordinary shares and ADSs are not affected by the name change. In connection with the name change, the Company expects to make additional ordinary course filings with the U.S. Securities and Exchange Commission.

About
Purple Biotech

Purple Biotech Ltd. (f/k/a Kitov Pharma Ltd.) (the “Company”; NASDAQ/TASE: KTOV) is a clinical-stage company focusing on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, to create successful long-lasting treatments for people with cancer. The Company’s oncology pipeline includes NT219 and CM24. NT219 is a small molecule targeting the novel cancer drug resistance pathways IRS1/2 and STAT3. The Company is currently advancing NT219 as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer (SCCHN) in a phase 1/2 study. CM24 is a monoclonal antibody blocking CEACAM1, a novel immune checkpoint that supports tumor immune evasion and survival through multiple pathways. The Company plans to advance CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in selected cancer indications in a phase 1 study followed by a phase 2 for the treatment of non-small cell lung cancer and pancreatic cancer. The Company has entered into a clinical collaboration agreement, as amended, with Bristol Myers Squibb for the planned phase 1/2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab (Opdivo®) in patients with non-small cell lung cancer and in combination with nivolumab in addition to nab-paclitaxel (ABRAXANE®) in patients with pancreatic cancer. The Company is also the owner of Consensi®, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension that was approved by the FDA for marketing in the U.S. Consensi® is being sold in the U.S. by Burke Therapeutics, the marketing partner of the Company’s U.S. distributor, Coeptis Pharmaceuticals. The Company has also partnered to commercialize Consensi in China and South Korea. The Company is relocating its corporate headquarters imminently to Rehovot, Israel. For more information, please visit http://www.kitovpharma.com.

Forward-Looking Statements and Safe Harbor Statement 

Certain statements in this press release that are forward-looking and not statements of historical fact are forward looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that are not statements of historical fact, and may be identified by words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies and objectives of management for future operations; product development for NT219 and CM24; the process by which early stage therapeutic candidates such as NT219 and CM24 could potentially lead to an approved drug product is long and subject to highly significant risks, particularly with respect to a joint development collaboration; the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length, progress and results of any clinical trials; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents obtained by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend issued patents; the commencement of any patent interference or infringement action against our patents, and our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory actions, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2019 and in our other filings with the U.S. Securities and Exchange Commission (“SEC”), including our cautionary discussion of risks and uncertainties under “Risk Factors” in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC’s website, http://www.sec.gov.

Company Contact:
Gil Efron
Deputy CEO & Chief Financial Officer
[email protected] +972-3-933-3121 ext. #105

Investor Relations Contact:
Chuck Padala
[email protected] 
+1 646-627-8390

LOS ANGELES, Dec. 10, 2020 (GLOBE NEWSWIRE) — (via InvestorWire) InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Stock2Me Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The Stock2Me Podcast features a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets. Stock2Me’s latest podcast features Ian Rosen, fintech and financial media expert. Rosen is former CEO of StockTwits.com, co-founder of Even Financial and former general manager of MarketWatch.

Throughout the interview, Rosen discussed business model changes that media companies must make in order to ensure their success going forward.

“I think historically most media companies built a content product, and that content was handed off to a different division to be monetized. That monetization could only happen without touching or thinking about or working with the content production group,” he said. “Instead, I think there’s a partnership that needs to be in play. That partnership will align the needs of the user or the reader and their demographic characteristics with ways that the reader or user can pay for that good content. So, the main thing that needs to change is an attitude of partnership between editorial and monetization.”

“The second thing, which goes hand-in-hand with that, is capital and the ability to upscale the organization, so it’s not dependent on third party ad-tech infrastructure to hand them dollars that are bigger than the dollars they handed them last year. Instead, they need to acquire the skills to generate those dollars themselves. Many organizations are just learning how to do that.”

Rosen offered a continued positive outlook for business and the economy in 2021, provided production and distribution of COVID-19 vaccines happen as planned.

“The market on an overall basis has done well, but a lot of people are suffering. I think the largest companies, primarily technology companies and retailers, have benefitted, because they have been allowed to stay open and from people’s ability to shop online. How many small businesses were closed when Walmart was open? How many were closed when Amazon is still open for shopping?”

“I do believe that there’s a huge pent up demand,” Rosen said. “It was reflected in the numbers for retail spending around Black Friday. A lot of people are staying home, and to the extent they’re still working, they’re saving money. They’re not spending on the things they usually spend on. When we’re all allowed to go back out normally, there’s going to be a heck of a lot of vacations booked and travel done and meals eaten in restaurants and drinks in bars. I think 2021 is going to look fantastic, if we get a vaccine.”

Rosen added that an expanding trend of personal empowerment will provide more opportunities for current and future investors than were available to previous generations.

“There’s a growing empowerment happening among people that’s affecting the investing market and the financial media market. There’s a growing desire to learn how to do things on your own, and that’s a good thing,” Rosen said. “I think to the extent that the financial media industry and the financial technology industry are helping to support and empower that trend in positive ways, then we’re all going to look forward to a much better financial life than our parents and grandparents had when they were reliant on more traditional and more limited options.”

Join InvestorBrandNetwork’s Stuart Smith and fintech and financial media expert Ian Rosen in exploring the continuing evolution of financial technology, advertising and commerce, particularly in the wake of the COVID-19 pandemic.

To hear the whole episode and subscribe for future episodes, visit: https://podcast.stock2me.com

The latest installment of The Stock2Me Podcast continues to reinforce InvestorBrandNetwork’s commitment to the expansion of its robust network of brands, client partners, followers and the growing IBN Podcast Series. For more than 15 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About InvestorBrandNetwork

The InvestorBrandNetwork (“IBN”) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.

For more information on IBN, visit https://www.InvestorBrandNetwork.com.

Please see full terms of use and disclaimers on the InvestorBrandNetwork website, applicable to all content provided by IBN wherever published or re-published: https://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]